6.53 USD
▼-0.02-0.31%
盘后 6.60 +1.07%
2026-09-15
市值
$357.53M
市盈率
—
EPS
-0.72
股息率
—
52 周区间
5.25 – 10.42
成交量
157.94K
Beta
0.97
目标价
15.50
52W 低 5.2552W 高 10.42
价格走势
公司简介
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment...